Mucous Membrane Pemphigoid - 12/09/13

Doi : 10.1016/j.cden.2013.07.003

Hong-Hui Xu, MD, PhD ^a,^b, Victoria P. Werth, MD ^b,^c,^⁎ , Ernesta Parisi, DMD ^d,^e, Thomas P. Sollecito, DMD, FDS RCSEd ^f
^a Department of Dermatology, No.1 Hospital of China Medical University, 155 North Nanjing Street, Shenyang 110001, China
^b Department of Dermatology, Philadelphia VA Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104, USA
^c Department of Dermatology, Perelman Center for Advanced Medicine, University of Pennsylvania, Suite 1-330A, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
^d Private Practice, 224 Union Boulevard, Totowa, NJ 07512, USA
^e Department of Diagnostic Sciences, NJ Dental School, UMDNJ, 110 Bergen Street, Newark, NJ 07103, USA
^f Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, 240 South 40th Street, Philadelphia, PA 19104, USA

^∗Corresponding author. Perelman Center for Advanced Medicine, University of Pennsylvania, Suite 1-330A, 3400 Civic Center Boulevard, Philadelphia, PA 19104.

Résumé

Mucous membrane pemphigoid (MMP) is chronic and frequently associated with exacerbations and remissions of clinical signs and symptoms. Clinicians should use pathologic and immunonologic techniques to help diagnose patients. Multidisciplinary collaboration is often necessary for the diagnosis and proper treatment of MMP. Systemic adjuvant immunosuppressive therapy is necessary for patients with progressive disease. In spite of the advances in available immunosuppressive medications and biologics, scarring is a significant complication in many cases. Surgical intervention is not curable; however, it may be necessary for restoring function and improving quality of life.

Le texte complet de cet article est disponible en PDF.

Keywords : Cicatricial pemphigoid, Mucous membrane, Subepithelial autoimmune disease, Oral, Ocular

Plan

Clinical presentation

Pharmacologic Strategies

Topical Agents

Systemic Medications

Nonpharmacologic Strategies

Self-Management Strategies

Evaluation, Adjustment, Recurrence

Summary

	Conflict of Interest: The authors have nothing to disclose.
	This material is supported by the National Institutes of Health, including NIH K24-AR 18 02207 (Werth), by the Department of Veterans Affairs, Veteran Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development and by Innovative Research Teams in Universities, Liaoning Bureau of Education (LT2012012).
	A version of this article appeared as Sollecito TP, Parisi E. Mucous membrane pemphigoid. Dent Clin N Am 2005;49:91–106.